- Home
- CANF vs MVSTW Comparison
CANF vs MVSTW Comparison
Compare CANF & MVSTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CANF | MVSTW |
|---|---|---|
| Founded | 1994 | 2006 |
| Country | Israel | United States |
| Employees | N/A | 1921 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CANF | MVSTW |
|---|---|---|
| Price | $0.26 | $0.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.25 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 126.0K |
| Earning Date | 02-03-2026 | 03-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $560,000.00 | ★ $370,989,000.00 |
| Revenue This Year | $461.72 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 39.03 |
| 52 Week Low | $0.25 | $0.35 |
| 52 Week High | $2.33 | $0.44 |
Technical Indicators
Market Signals| Indicator | CANF | MVSTW |
|---|---|---|
| Relative Strength Index (RSI) | 32.52 | 42.84 |
| Support Level | $0.26 | $0.10 |
| Resistance Level | $0.30 | $0.15 |
| Average True Range (ATR) | 0.02 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 12.19 | 42.82 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About MVSTW Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.